The Archer Foundation is honored to have distinguished science experts who serve on the advisory board. Our advisors bring a wealth of knowledge to the Foundation on current issues in neuroscience, funding gaps, strategic philanthropy, and promising research.
Dr. Regis Kelly, Ph.D., Advisor 2015 - Present
Dr. Regis B. Kelly is the Director of one of four California Institutes for Science and Innovation, created by the California Legislature to strengthen the academic foundation of its technology-based industries. QB3 is the only one of the four devoted exclusively to biology and to the life science industries. It is an innovation center made up of over 200 quantitative biologists at three northern California campuses (UCB, UCSC & UCSF) working at the interface of the physical and biological sciences and a team of professionals converting its discoveries into practical benefits for society.
From 2001 to 2004, Dr. Kelly served as Executive Vice Chancellor at the University of California in San Francisco, where his major responsibility was the new Mission Bay campus.
From 1995 to 2000, Dr. Kelly served as Chair of the Department of Biochemistry and Biophysics at UCSF; from 1988 to 1995, he was the Director of UCSF’s Cell Biology Graduate Program; and from 1992 to 2000, he was the Director of the Hormone Research Institute at UCSF. He has published extensively in the areas of cell and neurobiology.
Dr. Kelly received his undergraduate degree in Physics from the University of Edinburgh in Scotland in 1961 and his Ph.D. in Biophysics from the California Institute of Technology in 1967. Following a post-doctoral fellowship at Stanford, Dr. Kelly was an instructor in the Department of Neurobiology at Harvard. He has served as Chairman of the Bay Area Scientific Innovation Consortium (BASIC) and on the Boards of the Malaysian Biotechnology Industry Advisory Board, the Scleroderma Research Foundation, Bridge Pharmaceuticals, the San Francisco Mayor’s Biotechnology Advisory Group and the San Francisco China Desk, among others. He is also a General Partner of Mission Bay Capital venture fund.
Dr. Frank Longo, M.D., Ph.D., Advisor 2017 - Present
Dr. Longo is Professor and Chairman, Department of Neurology and Neurological Sciences at Stanford University, and serves on the Advisory Committee for the Stanford Neurosciences Institute. He completed his neurology training in the Department of Neurology at UCSF where he also served as professor and vice chair. Since 2006 he has been chair of the Department of Neurology and Neurological Sciences at Stanford.
While at Stanford, Dr. Longo has led the recruitment of close to 100 faculty and has overseen the development of major clinical programs in stroke, epilepsy, Alzheimer’s, Parkinson’s, autonomic disorders, and other neurological areas. These programs have made possible the first accreditation of the first Comprehensive Stroke Program in the US, national designation of a Level 4 Comprehensive Epilepsy Center, and the recent award of a NIH Alzheimer’s Disease Research Center (ADRC). He has also prioritized excellence in education with Stanford School of Medicine students rating neurology as their top clinical core rotation for the past six years in a row.
In the area of research, Dr. Longo has led a major research expansion in Stanford neurology with the department recently ranked among the top 5 in the US in NIH funding. Within his own research efforts, Dr. Longo is one of the rare physician-scientists who has created a new therapeutic approach that has not only been successful in mice, but has actually advanced to testing into human trials. With support from the NIH, Alzheimer’s Drug Discovery Foundation (ADDF), Alzheimer’s Association, and generous donations, he and his team have pioneered an entirely new pharmaceutical approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders. He founded PharmatrophiX, with his wife Anne Longo as CEO, a company focused on the commercial development of treatments for Alzheimer’s and other diseases. In 2015, Dr. Longo was the recipient of the inaugural Goodes Prize for Excellence in Alzheimer’s Drug Discovery from the ADDF. In February 2016, his lead drug was featured on the cover of Time Magazine.
Mr. Douglas K. Freeman, J.D., LL.M., Advisor 2015 - 2017
Doug Freeman currently serves as founding Executive Chair and Chief Executive Officer of Orange County Music and Dance, a public charity created in 2016 and located in Irvine, California. OC Music and Dance is the first and only nonprofit community school in Orange County, offering a comprehensive program in music, dance, voice, film and theater, along with adult programs in health and well-being.
Most recently, Mr. Freeman served as Executive Vice President and Director of Consulting for First Foundation Bank from 2008-2016. In that role, he also served as Director of Trust Services. Doug provided strategic planning and organizational management advice for business, public charities, private foundation, and family clients. From 1970 until 2008, Mr. Freeman practiced as a tax attorney. In 1976, he co-founded the law firm Freeman, Freeman & Smiley, LLP in Los Angeles. From 2005 through 2008, he was recognized by Worth magazine as among the 100 top attorneys in the United States, and in 1999, he was featured by Bloomberg Financial as one of the nation’s leading estate planning attorneys.
In 1981, Mr. Freeman began a five year effort to establish a day to honor and recognize individuals, families, and businesses for their generosity of time, talent and treasure. In 1986, this effort culminated in the creation of National Philanthropy Day, passed by Congress and signed by President Ronald Reagan. That day is celebrated in every state in most metropolitan areas, as well as Canada and Mexico.
Mr. Freeman currently serves as a board member of three private foundations, two of which he chairs and is CEO. Over his career, he served as board member of over a dozen public charities, and as chairman of several, and is Life Director of both the California Institute of the Arts and Orange County’s Pacific Symphony. More recently, Doug was Chairman of the Board of Trustees for the University of California, Irvine Foundation and later chaired its successful $1 billion capital campaign.
Mr. Freeman served as Adjunct Professor of Law at the University of California, Irvine School of Law, where he taught a course entitled Organization, Management and Tax Aspects of Public Charities and Private Foundations. He has authored two books, and co-authored a third book with Dr. Lee Hausner, entitled The Legacy Family: The Definitive Guide to a Successful Multigenerational Family.
Dr. Zach Hall, Ph.D., Advisor 2015 - 2016
Dr. Zach Hall, who served as an Archer Board Advisor in 2015-2016, completed his B.S. degree in English at Yale University in 1958, and completed a Ph.D. in biochemistry at Harvard in 1966. He moved to the West Coast and worked as a fellow in biochemistry at Stanford University from 1967 to 1968. After his postdoctoral training, he joined the faculty of the Department of Neurology at the Harvard Medical School, serving there for eight years. In 1976, Zach Hall was recruited to UCSF’s Department of Physiology to head a new Division of Neurobiology. At UCSF he created an interdepartmental neuroscience program, which led to UCSF’s rise to national leadership in the field, and acted as a model for stimulating cross-disciplinary research. 1987 he became Chair of the Department of Physiology, and in 1994 became head of the Biomedical Sciences Graduate Program.
In 1994 he was appointed Director of the National Institute of Neurological Disorders and Stroke, an institution that had been in the forefront of brain research since 1950. As Director of NINDS he managed 23 intramural institute branches and laboratories with a staff of 700 scientists, physicians, and administrators, as well as supervising research funding in public and private institutions across the country. Noting the exciting state of neuroscience at this time, Hall stated that, “our job will be to provide the scientific leadership and institutional support to sustain these advances.”
Dr. Hall returned to UCSF in 1998 to serve as Executive Vice Chancellor for Research, intent on making the developing Mission Bay campus “the most exciting and vibrant place in biomedical research.” In 2001 Dr. Hall became President and CEO of En Vivo Pharmaceuticals, a startup biotechnology company for developing drugs for neurodegenerative disease. From 2002 to 2005 he moved to southern California to be Senior Associate Dean for Academic Development and also Director of the Zilkha Neurogenetic Institute at the Keck School of Medicine at USC. From 2005 to 2007 he was first President of the California Institute for Regenerative Medicine, which was set up as a state agency for funding stem cell research in California under state Proposition 71.
During his varied career as educator, investigator, and senior statesman of neuroscience, Dr. Hall has published more than 100 papers and reviews, and made fundamental contributions to the investigation of the neuromuscular junction. He has written the textbook An Introduction to Molecular Neurobiology, and was a founding editor of the journal Neuron. He has been a member of the scientific advisory committee for Neurobiology of the Howard Hughes Medical Institute, the Max-Planck Institutes in Germany, and the RIKEN Institute in Japan. He is a member of the Institute of Medicine, the American Academy of Arts and Sciences, the American Neurological Association and a Fellow of the American Association for the Advancement of Science. In 2003 he received the Purkynje Medal for Scientific Achievement from the Czech Academy of Science.